Speech-Language Pathologists in Rogers City, MI Accepting Medicare

4 Speech-Language Pathologists found. Showing 1 - 4

Ms. Jennifer Beaujean, M.A., CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 555 N Bradley Hwy, Rogers City, MI 49779 Phone: 989-834-2151

Ms. Jeanne L Longtin, MACCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 555 N Bradley Hwy, Suite C, Rogers City, MI 49779 Phone: 989-734-7545    Fax: 989-734-7648

Emilie P Cline Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 555 N Bradley Hwy, Rogers City, MI 49779 Phone: 989-734-2151

Mrs. Shelby M Carrier, M.A. CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 145 Doris Ln, Rogers City, MI 49779 Phone: 906-287-1177

News Archive

Doubts raised over Lap-Band surgery in the long term: Study

This surgery is based on the principle of placing a silicone band around the top portion of the stomach to restrict food intake. It has become an increasingly popular option in the battle against obesity, but some experts have worried about its safety.

CT scans increase risk of radiation-induced cancer in young children, study finds

According to a study of seven U.S. healthcare systems, the use of computed tomography scans of the head, abdomen/pelvis, chest or spine, in children younger than age 14 more than doubled from 1996 to 2005, and this associated radiation is projected to potentially increase the risk of radiation-induced cancer in these children in the future, according to a study published Online First by JAMA Pediatrics, a JAMA Network publication.

Scientists discover gene for Parkinson's disease

UCL scientists have discovered a new gene implicated in the early development of Parkinson's disease. In a study of families with early onset disease, Professor Nick Wood and colleagues at University College London's Institute of Neurology identified a novel gene which produces a malfunctioning protein that could pave the way for new treatments for Parkinson sufferers.

FDA approves Alexion's Soliris drug for treatment of atypical hemolytic uremic syndrome

Alexion Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved the Company's supplemental Biologics License Application (sBLA) providing regular approval for Soliris® (eculizumab) for the treatment of adult and pediatric patients with atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy (TMA).

Read more Medical News

› Verified 7 days ago